
Update on Management of Cast Nephropathy

Nelson Leung Professor of Medicine Division of Nephrology and Hypertension/ Hematology

17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019




Renal Function in Newly Diagnosed MM Patients




Tabriz , Iran 19-22 November 2019


Renal impairment increases with more advanced disease



Renal Pathologies in Myeloma Patients



Risk of Cast Nephrology by sFLC level



Serum FLC levels (mg/L)

Leung et al. Kidney Int 2008 Yadav et al. BMC Nephrol 2018





International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

The criteria have also been updated to clarify that only renal failure caused by light-chain cast nephropathy (based on typical histological changes or presumptive diagnosis based on the presence of high involved FLC levels, typically >1500 mg/L) is regarded as a myeloma-defining events. Although other forms of renal damage (eg, AL amyloidosis, monoclonal immunoglobulin deposition disease, lightchain Fanconi syndrome, monoclonal gammopathyassociated membranoproliferative glomerulonephritis) can occur in multiple myeloma, this association is not characteristic of multiple myeloma and can be seen with other types of plasma cell dyscrasias (eg, MGUS) or lymphoproliferative disorders. Although they can occur in conjunction with multiple myeloma, in most patients they occur independently without evidence of other myelomadefining events. For this reason, these renal disorders are not regarded as myeloma-defining events, and should not lead to multiple myeloma diagnosis, unless they meet criteria for multiple myeloma as listed in the panel. These


International Congress of Nephrology, Dialysis, and Transplantation

Tabriz, Iran 19-22 November 2019




Rajkumar et al. Lancet Oncol 2014

Monoclonal FLC and Cast Nephropathy




Relationship between serum FLC and serum creatinine







Clonal tiding




GD


International Socie Dif spherology Iran a (3 pk lety of Nephrology

IPNA

17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019

Light Chain Cast Nephropathy





Copyright © 1998 by the National Kidney Foundation

17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019




Renal biopsy of patients with multiple myeloma

Pathologic Diagnosis	No. of Patients (%)	
Paraprotein-associated renal lesions		
Myeloma cast nephropathy	62 (33)	
Monoclonal immunoglobulin	41 (22)	
deposition disease		
Amyloidosis	40 (21)	
Fibrillary glomerulonephritis	2 (1)	
Immunotactoid glomerulopathy	1 (0.5)	
Light chain proximal tubulopathy	1 (0.5)	
Interstitial infiltration by malignant	2 (1)	
plasma cells		

Nasr et al. Am J Kidney Dis 2012


MAYO CLINIC

Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases



Tabriz, Iran 19-22 November 2019

Impact of Renal Impairment on Overall Survival




Blade et al. Arch Int Med 1998




ORIGINAL ARTICLE

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?



International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019 International Society of Rephrology Iranian Society of Nephrology

Reversing Renal Impairment Improves Overall Survival



Blade et al. Arch Int Med 1998 Knudsen et al. Eur J Haematol. 2000


MAYO

17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019

ESRD due to Multiple Myeloma in the United States, 2001–2010

Scott Reule,*[†] Donal J. Sexton,*[†] Craig A. Solid,[†] Shu-Cheng Chen,[†] and Robert N. Foley*[†]

*Department of Medicine, University of Minnesota, Minneapolis, Minnesota; and [†]Minneapolis Medical Research Foundation, Minneapolis, Minnesota



17th

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

Response	Baseline eGFR* (ml/min/1.73 m ²)	Best CrCl Response (mL/min)
CRrenal	< 50	≥ 60
PRrenal	< 15	30-59
MRrenal	< 15	15-29
	15-29	30-59




Dimopoulos et al. JCO 2010

Renal Response by Hematologic Response

Final eGFR by

hematologic response


- >VGPR 59.5 ml/min/1.73m² -
- $PR/MR 38.9 ml/min/1.73m^2 -$
- SD/PD 16.8 ml/min/1.73m² -



Ludwig et al. JCO. 2010



Improvement of acute renal function in patients with MM




Leung et al. Kidney Int 2008

MAYO



Probability of Renal Response by Depth and Speed of sFLC Reduction




Hutchison et al. J Am Soc Nephrol 2011

17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz, Iran 19-22 November 2019



Why is early reduction of FLC important for renal recovery?




MCP-1

/TD International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019



Signal Pathway induced by Free Light Chains




17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019 Sanders et al. Blood 2011

nal Society of Rephrology Iranian Society

MAYO CLINIC

Bortezomib





VISTA MP vs VMP

	VMP		MP	
	Normal	RI	Normal	RI
ISS III	21%	62%	22%	54%
≤ 30 ml/min		84%		80%
Overall Response	72%	68%	29%	46%
CR	30%	31%	3%	5%
≤ 30 ml/min		37%		13%
First response	1.4m	1.0m	4.9m	3.4m
Median TTP	NE	19.9m	18.0m	16.1m
Median OS	NE	NE	NE	31.9m


* Serum Cr \leq 2.0 mg/dL



JOURNAL OF CLINICAL ONCOLOGY

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study


Heinz Ludwig, Zdenek Adam, Roman Hajek, Richard Greil, Elena Tóthová, Felix Keil, Eva Maria Autzinger, Josef Thaler, Heinz Gisslinger, Alois Lang, Miklós Egyed, Irene Womastek, and Niklas Zojer





Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Christof Scheid,¹ Pieter Sonneveld,² Ingo G.H. Schmidt-Wolf,³ Bronno van der Holt,² Laila el Jarari,² Uta Bertsch,⁴ Hans Salwender,³ Sonja Zweegman,² Igor Wolfgang Blau,³ Edo Vellenga,² Katja Weisel,³ Michael Pfreundschuh³, Kon-Siong Jie,² Kai Neben,⁴ Helgi van de Velde,⁵ Ulrich Duehrsen,³ M. Ron Schaafsma,² Walter Lindemann,³ Marie José Kersten,² Norma Peter,³ Mathias Hänel,³ Sandra Croockewit,² Hans Martin,³ Shulamiet Wittebol,² Gerard MJ Bos,² Marinus van Marwijk-Kooy,² Pierre Wijermans,² Hartmut Goldschmidt,⁴ and Henk M. Lokhorst²




Scheid et al. Haematologic 2014

MAYO

Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

Patrizia Tosi, Elena Zamagni, Paola Tacchetti, Michela Ceccolini, Giulia Perrone, Annamaria Brioli, Maria Caterina Pallotti, Lucia Pantani, Alessandro Petrucci, Michele Baccarani, Michele Cavo




17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz, Iran 19-22 November 2019



ORIGINAL ARTICLE

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

WI Gonsalves, N Leung, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, D Dingli, P Kapoor, RS Go, Y Lin, SJ Russell, JA Lust, S Zeldenrust, RA Kyle, MA Gertz and SK Kumar



Govsalves et al. Blood Cancer J 2015

al Society of Rephrology Iranian Society of I

MAYO CLINIC


Lenalidomide and Dexamethasone in Patients with Renal Impairment

MM-009 and MM-010 $\, \bullet \,$

- RD vs D -
- 353 patients randomized to RD -
- Renal function calculated by Cockcroft Gault equation
 - Scr cutoff for the studies was < 2.5 mg/dl -
 - Treatment –
- Median dose for patient with CrCl > 30 ml/min = 25 mg/d •
- Median dose for patient with CrCl < 30 ml/min = 15 mg/d $\,$ $\, \bullet \,$

The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function

Meletios Dimopoulos, MD¹; Adrian Alegre, MD²; Edward A. Stadtmauer, MD³; Hartmut Goldschmidt, MD⁴; Jeffrey A. Zonder, MD⁵; Carlos M. de Castro, MD⁶; Zvenyslava Masliak, MD⁷; Donna Reece, MD⁸; Marta Olesnyckyj, RN⁹; Zhinuan Yu, PhD⁹; and Donna M. Weber, MD¹⁰



Dimopoulos et al. Cancer 2010

Society of Rephrology Irania

MAYO

Toxicity of RD in Renally Impaired Patients

Adverse Event	Mild or No RI: CL _{Cr} ≥60 mL/min	Moderate RI: CL _{Cr} ≥30 mL/min to <60 mL/min	Severe RI: CL _{Cr} <30 mL/min
Total no. of patients	243	82	16
Hematologic toxicities, %			
Neutropenia	32	48 ^a	38
Thrombocytopenia	9	22 ^a	38 ^a
Anemia	5	21 ^a	44 ^a
Nonhematologic toxicities, %			
Thrombotic events ^b	13	15	6
Hypertension NOS	0.8	2	13
Atrial fibrillation	3	4	13
Fatigue	5	12 ^a	0
Asthenia	4	5	13
Constipation	2	1	13
Hypocalcemia	3	6	19
Dehydration	0.8	2 ^a	13 ^a
Pneumonia NOS	7	9	25 ^a
Clinically important adverse events, %			
Febrile neutropenia	3	2	0
Neuropathy	2	2	0
Peripheral neuropathy	2	1	0

RI indicates renal impairment; CL_{Cr}, creatinine clearance; NOS, not otherwise specified.

 ^{a}P < .05 versus patients with mild or no RI.

^b Thrombotic events included pulmonary embolism, deep vein thrombosis, and venous thrombosis NOS.

MAYO


imopoulos et al. Cancer

IPNA

ORIGINAL ARTICLE

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

MA Dimopoulos, M Roussou, M Gkotzamanidou, N Nikitas, E Psimenou, D Mparmparoussi, C Matsouka, M Spyropoulou-Vlachou, E Terpos and E Kastritis



	Thalidomide	Bortezomib	Lenalidomide	P-value
Baseline eGFR (ml/min/1.73 m ²), median(range)	38 (6–59)	21 (4–59)	37 (6–58)	0.037
Best eGFR (ml/min/1.73 m ²), median(range)	69 (16–140)	77 (5–175)	45 (15–106)	0.2
Renal response (≥renalMR)	46 (74%)	35 (81%)	17 (61%)	0.153
Major renal response (≥renalPR)	34 (55%)	33 (77%)	12 (43%)	0.011
RenalCR	33 (53%)	29 (67%)	10 (36%)	0.032
Baseline eGFR (ml/min/1.73 m ²) for patients who achieved renalCR, median (range)	44 (6–58)	27 (5–59)	49 (15–58)	
Best eGFR (ml/min/1.73 m ²) for patients who achieved renalCR, median (range)	86 (64–139)	91 (61–175)	85 (65–106)	

Dimopoulos et al. Leukemia 2103

anal Society of Rephrology Iranian Society of Nephrology

MAYO

IPNA



Factors associated with a major renal response


	Univariate		Multivariate	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age < 65 years	5.08 (1.93–25.7)	0.001	3.39 (1.070–10.75)	0.038
eGFR≥30 ml/min	2.3 (1.024-4.123)	0.043	2.93 (1.28-6.7)	0.011
24-h Urine (Bence Jones Protein)≥2g	0.892 (0.387-1.8)	0.639	NA	
Light chain only myeloma	1.393 (0.59–3.289)	0.449	NA	
Myeloma response (≥PR)	3.05 (1.37–6.8)	0.006	2.65 (1.08–6.49)	0.033
Dexamethasone dose ≥160 mg	3.072 (1.36–6.93)	0.007	1.74 (0.64–4.5)	0.256
Lenalidomide	1		1	
Thalidomide	1.62 (0.66-3.98)	0.294	2.36 (0.868-6.405)	0.092
Bortezomib	4.4 (1.571–12.324)	0.005	4.25 (1.3–13.94)	0.017



Dimopoulos et al. Leukemia 2103



Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial



Scheid et al. Haematologica 2014


al Society of Rephrology Iranian Soci

MAYO

ORIGINAL ARTICLE

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

WI Gonsalves, N Leung, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, D Dingli, P Kapoor, RS Go, Y Lin, SJ Russell, JA Lust, S Zeldenrust, RA Kyle, MA Gertz and SK Kumar



Gonsalves et al. Blood Cancer J 2015

I Society of Rephralogy

MAYO

Plasmapheresis

3 randomized trials



Zucchelli Study

- Randomized Trial •
- -29 patients
- -Methylprednisolone and cyclophosphamide
- -2 to 5 L/d of NS or sodium bicarbonate
- -500 mg to 1500 mg of furosemide
- -17 patients had renal biopsies
- -15 received 5 PLEX (more if necessary)
- -14 dialysis dependent



Results

Control Group

2 recovered enough renal

function to stop dialysis

3 died within the first month of study

2 more died during the second month



11/13 dialysis dependent patients recovered renal function

Renal recovery period ranged from 9 to 34 days

1 died within 2 months of study



Johnson's Study

21 patients

Melphalan & Prednisone

 $\frac{1}{2}$ NS with HCO₃⁻

Furosemide to achieve urine output of 100 cc/h

- Renal biopsy was performed on 16 patients
- Randomization

Control – 10

PLEX - 11



Results

Improvement in renal function

Control – 5

PLEX – 7

Patients who were chemo-responsive were more likely to have improvement in renal function

Of the 12 patients on HD, only patients (3) who received PLEX were able to discontinue dialysis

Patients with lower histologic score were more likely to recover renal function

No differences in survival was noted between the 2 groups





Annals of Internal Medicine

Article

Plasma Exchange When Myeloma Presents as Acute Renal Failure A Randomized, Controlled Trial

William F. Clark, MD; A. Keith Stewart, MD; Gall A. Rock, MD; Marion Sternbach, MD; David M. Sutton, MD; Brendan J. Barrett, MD; A. Paul Heidenheim, MA; Amit X. Garg, MD; David N. Churchill, MD; and the Canadian Apheresis Group

Ann Intern Med. 2005;143:777-784.

Multicenter prospective trial Chemo: VAD vs M&P 104 Patients 7 patients withdrew from the study 3 withdrew from the study 2 patients in each arm were lost to F/U 58 PLEX :39 Control Composite outcome

Death, Dialysis, eGFR < 30 ml/min/1.73m²



Results

<u>PLEX</u>	<u>Control</u>	
65.2	61.3	Age
4.78	5.21	Initial Scr (mg/dL)
41.4%	43.6%	Durie-Salmon IIIb
57.9%	69.2%	Composite outcome
32.8%	33.3%	Death at 6 months
41.6%	38.6%	Discontinued dialysis
31.4	30.2	eGFR at 6 months (ml/min/1.73m ²)



Conclusion

In our randomized, multicenter clinical trial of 97 participants from 14 centers in Canada, plasma exchange in myeloma-associated acute kidney failure showed no clinically meaningful difference for the primary composite outcome of death, dialysis dependence, or GFR less than 0.29 mL \cdot s⁻² \cdot m⁻² (<30 mL/min per 1.73 m²) at 6 months,




Problems with Clark's study

Renal biopsy rate was low

Serum free light chain was not used to measure response



Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients




International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019 Ecotiere et al. NDT 2016


nternational Society of Rephrology Iranian Society of Nept

see commentary on page 1211


Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains



Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: *In Vitro* and *In Vivo* Studies








Hutchison et al. JASN 2007






Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis



Hutchison et al. CJASN 2009



MYRE Trial



Bridoux et al. JAMA 2017


al Society of Rephrology Iranian Society of N

MAYO CLINIC

76

IPNA

EuLITE trial




Hutchison et al. Lancet Haematol 2019

al Society of Rephrology Iranian Society of N

MAYO CLINIC

IPNA

Difference in Overall Survival between MYRE and EuLITE



Hutchison et al. Lancet Haematol 2019 Bridoux et al. JAMA 2017



7th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019

Hematologic Responses between EuLITE and MYRE

	60.9%
	43.7%
37%	69.6%*
62%	47.9%
35%	
62%*	
	62%

* P < 0.05

Hutchison et al. Lancet Haematol 2019 Bridoux et al. JAMA 2017



Prescription of the Therapy

	MYRE	EuLITE
Chemotherapy	VD*/VCD	BDD
HCO Dialyzer	2.1 m ² Theralite Gambro	Two 1.1 m ² Baxter Gambro HCO 1100
Frequency of dialysis	5h x 8 sessions first 10 days then 3x/ week	6h day 0 8h days 2,3, 5-7, 9, 10 then 6 h 3x/week
Penicillin	Prophylaxis	No
Cotrimazole	Prophylaxis	480 mg 3x/week
Albumin	20 g	60 g

MAYO CLINIC

al Society of Rephralogy

* First 3 cycles




Adverse events between EuLITE and MYRE

RR - 4.64 95% CI1.42 - 15.20 P = 0.008

	HCO-HD	HF-HD	Total
Between 0 and 90 days*			
Infections	26 (58%)	13 (39%)	39 (50%)
Catheter-related	5 (11%)	3 (9%)	8 (10%)
Lung	14 (31%)	3 (9%)	17 (22%)
Sepsis	1(2%)	2 (6%)	3 (4%)
Other	6 (13%)	5 (15%)	11 (14%
Not infections	19 (42%)	20 (61%)	39 (50%)
Cardiovascular and thrombotic	3 (7%)	3 (9%)	6 (8%)
Gastrointestinal	3 (7%)	1 (3%)	4 (5%)
Haematological	0	0	0
Musculoskeletal	5 (11%)	3 (9%)	8 (10%)
Neurological	1(2%)	1(3%)	2 (3%)
Other organ systems	7 (16%)	12 (36%)	19 (24%)

Chemotherapy was prematurely discontinued because of toxic effects in 5 patients (3 in the high-cutoff hemodialysis group and 2 in the conventional hemodialysis group). The incidence of grade 3 or greater cytopenia and infectious complications was not significantly different. Grade 3 or greater peripheral neuropathy was observed in 1 patient in the high-cutoff hemodialysis group and in 4 patients in the conventional hemodialysis group. At least 1 serious adverse event was recorded in 39% of the patients in the high-cutoff hemodialysis group and in 37% of the patients in the conventional hemodialysis group.


Difference in Early Survival between MYRE and EuLITE



17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz, Iran 19-22 November 2019



Early Mortality in Myeloma Patients with Renal Failure



17th International Congress of Nephrology, Dialysis, and Transplantation Tabriz , Iran 19-22 November 2019



Potential Future Therapy

- Cyclized Peptide •
- Targets the binding site on THP
- Coadministration of CCP with FLC prevents the development of acute kidney injury
- Reversal of kidney injury with CCP is observed up to 4 hours after injection of FLC



MAYO IPNA MAYO et alsoclin Invest2012 Lettrig in 10 ettrig in 10 ettri

Thank you for your attention

Welcome to mSMART: The Risk Adapted Approach to Management of Multiple Myeloma and Related Disorders

Ailawadhi, Sikander, M.D. Bergsagel, Leif, M.D. Buadi, Francis, M.D. Chanan-Khan, Asher, M.D. Chesi, Marta, Ph.D. Dalton, Robert, M.D. Dingli, David, M.D., Ph.D. Dispenzieri, Angela, M.D. Drake, Matthew, M.D., Ph.D. Fonseca, Rafael, M.D. Gertz, Morie, M.D. Go, Ronald, M.D. Hashmi, Shahrukh, M.D. Hayman, Suzanne, M.D. Hwa, Lisa, RN-CNP Kapoor, Prashant, M.D. Kumar, Shaji M.D.

Kyle, Robert, M.D. Lacy. Martha. M.D. Leung, Nelson, M.D. Lin, Yi, M.D., Ph.D. Lust, John, M.D., Ph.D. Mikhael, Joseph, M.D. Rajkumar, S. Vincent, M.D. Reeder, Craig, M.D. Roy, Vivek, M.D. Russell, Stephen, M.D., Ph.D. Sher, Taimur, M.D. Siddiqui, Mustageem, M.D. Stewart, Keith, MB ChB Thome, Stephan, M.D. Witzig, Thomas, M.D. Zeldenrust, Seven, M.D., Ph.D.



MISSION

Our MISSION is to present the state of the art approach to management of these plasma cells disorders including Myeloma, Amyloidosis, and Waldenstroms Macroglobulinemia. Views expressed here are opinions of a group of experts, based on best available evidence





Questions



Scottsdale, Arizona



Rochester, Minnesota



Jacksonville, Florida



